Detection of Novel Antigen MLAA-34 Gene Mutation in Acute Monocytic Leukemia and Its Correlation with Efficacy.
- VernacularTitle:急性单核细胞白血病新抗原MLAA-34基因突变的检测及其与疗效相关性的研究
- Author:
Bo LEI
1
;
Wang-Gang ZHANG
2
;
Yin-Xia CHEN
1
;
Ai-Li HE
1
;
Xing-Mei CAO
1
;
Wan-Hong ZHAO
1
;
Jian-Li WANG
1
;
Jie LIU
1
;
Xiao-Rong MA
1
;
Yun YANG
1
;
Peng-Yu ZHANG
1
;
Jing LUO
1
;
Xin MENG
1
Author Information
- Publication Type:Journal Article
- From: Journal of Experimental Hematology 2018;26(1):97-104
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo investigate the correlation of all exone mutation in MLAA-34 gene with chemotherapeutic efficacy for leukemia.
METHODSThe expression level of MLAA-34 gene in 40 patients with AML-M5 and 5 healthy volunteers as control was detected by RT-PCR and its effect on chemotherapeutic efficacy were analyzed by RT-PCR; the effect of MLAA-34 gene mutation on overall survival (OS) and progression-free survival (PFS) of AML-M5 patients was analyzed by sequencing of all 12 exoues in MLAA-34 gene, the correlation between the mutation of prognostic genes important to leukemia and the mutation of MLAA-34 gene was explored.
RESULTSThe expression level of MLAA-34 gene was significantly up-regulated as compared with that of healthy volunteers, moreover this up-regulation was related with a C59T SNP site located in second exon of MLAA-34 gene, meanswhile this SNP site is affinitive to the well-known mdecular markers of AML, inclinding Fms-like tyrosine kinase (FLT-3) and DNA methyltransferase-3A(DNAMT3A). The AML-M5 patients with high expression of MLAA-34 gene poorly responded to chemotherapy, the AML-M5 patients with MLAA-34 C59T mulation had even more high expression of MLAA-34 gene and significantly short OS and PFS in comparison with those of patients without C59T mutation.
CONCLUSIONThe C59T mutation in MLAA-34 gene is a high risk factor for recurrence of AML, and may be a cadidate target for treatment of AML.